Al(OH)3-adjuvanted vaccine-induced macrophagic myofasciitis in rats is influenced by the genetic background

Neuromuscular Disorders

Volumn 16, Issue 5, 2006, Pages 347-352

  Authier, François Jérôme ^a,b   Sauvat, Stéphane ^b   Christov, Christo ^b   Chariot, Patrick ^b   Raisbeck, Grant ^c   Poron, Marie Françoise ^a   Yiou, Françoise ^c   Gherardi, Romain ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c CENTRE DE CALCUL DE L INSTITUT NATIONAL DE PHYSIQUE NUCLEAIRE ET DE PHYSIQUE DES PARTICULES   (France)

Author keywords

Adverse effects; Aluminium hydroxide; Experimental model; Histopathology; Inflammatory myopathies; Lewis rat; Macrophagic myofasciitis; Morphometry; Radioisotopic study; Sprague Dawley rat; Th1; Th2; Vaccine

Indexed keywords

ALUMINUM; ALUMINUM HYDROXIDE; IMMUNOLOGICAL ADJUVANT; RADIOISOTOPE; RECOMBINANT HEPATITIS B VACCINE; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL MODEL; FASCIITIS; FEMALE; HEREDITY; HISTOPATHOLOGY; IMMUNE RESPONSE; INJECTION SITE INFLAMMATION; INTRACELLULAR TRANSPORT; ISOTOPE ANALYSIS; MACROPHAGE; MACROPHAGIC MYOFASCIITIS; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; STRAIN DIFFERENCE; TH1 CELL; TH2 CELL; VACCINATION REACTION; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; LEWIS RAT; MYOFASCIAL PAIN; PATHOLOGY; PATHOPHYSIOLOGY; SKELETAL MUSCLE; SPRAGUE DAWLEY RAT;

ALUMINUM HYDROXIDE; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; IMMUNITY, CELLULAR; INJECTIONS, INTRAMUSCULAR; MACROPHAGES; MUSCLE, SKELETAL; MYOFASCIAL PAIN SYNDROMES; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TH2 CELLS; VACCINES;

EID: 33646167377     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2006.02.004     Document Type: Article

References (33)

1. Gherardi R.K., Coquet M., Chérin P., et al. Macrophagic myofasciitis: an emerging entity. Lancet 352 (1998) 347-352
2. Gherardi R.K., Coquet M., Cherin P., et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 124 (2001) 1821-1831
3. Bassez G., Authier F.J., Lechapt-Zalcman E., et al. Inflammatory myopathy with abundant macrophages (IMAM): a condition sharing similarities with cytophagic histiocytic panniculitis and distinct from macrophagic myofasciitis. J Neuropathol Exp Neurol 62 (2003) 464-474
4. WHO Vaccine Safety Advisory Committee. Macrophagic myofasciitis and aluminum-containing vaccines. Wkly Epidemiol Rec 1999;74:338-40.
5. Gherardi R.K., and Authier F.J. Aluminium inclusion macrophagic myofasciitis: a recently identified condition. Immunol Allergy Clin North Am 23 (2003) 699-712
6. Verdier F., Burnett B., Michelet-Habchi C., Moretto P., Fievet-Groyne F., and Sauzeat E. Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. Vaccine 23 (2005) 1359-1367
7. World Health Organization. Immunological adjuvants. Technical report series 595. Geneva: World Health Organization; 1976.
8. Balouet G., Baret M., Relyveld E., Ravisse P., and Levaditi J. Rôle des antigènes et des substances adjuvantes dans la réponse histologique au cours des granulomes experimentaux ('granulome immunogène'). Ann Anat Pathol (Paris) 22 (1977) 159-170
9. Schijns V.E.J.C. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 12 (2000) 456-463
10. Hamilton J.A., Byrne R., and Whitty G. Particulate adjuvants can induce macrophage survival, DNA synthesis, and a synergistic proliferative response to GM-CSF and CSF-1. J Leukoc Biol 67 (2000) 226-232
11. Ulanova M., Tarkowski A., Hahn-Zoric M., and Hanson L.A. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 69 (2001) 1151-1159
12. Cherin P., Authier F.J., Gherardi R.K., et al. Gallium-67 scintigraphy in macrophagic myofasciitis. Arthritis Rheum 43 (2000) 1520-1526
13. Unanue E.R. Antigen-presenting cells. In: Delves P.J., and Roitt I.M. (Eds). Encyclopedia of immunology. 2nd ed (1998), Academie Press, San Diego 175-178
14. Fournie G.J., Cautain B., Xystrakis E., et al. Cellular and genetic factors involved in the difference between Brown Norway and Lewis rats to develop respectively type-2 and type-1 immune-mediated diseases. Immunol Rev 184 (2001) 145-160
15. Smil V. Laying down the law. Nature 403 (2000) 597
16. Schwaeble W., Schafer M.K., Petry F., et al. Follicular dendritic cells, interdigitating cells, and cells of the monocyte-macrophage lineage are the C1q-producing sources in the spleen. Identification of specific cell types by in situ hybridization and immunohistochemical analysis. J Immunol 155 (1995) 4971-4978
17. 26Al. Clin Chem 43 (1997) 1023-1028
18. Nielsen B.S., Lund L.R., Christensen I.J., et al. A precise and efficient stereological method for determining murine lung metastasis volumes. Am J Pathol 158 (2001) 1997-2003
19. Motulsky H.J., and Christopopoulos A. Fitting models to biological data using linear and non-linear regression. A practical guide to curve fitting (2003), GraphPad Software Inc., San Diego CA. www.graphpad.com
20. Seeber S.J., White J.L., and Hem S.L. Solubilization of aluminum-containing adjuvants by constituents of interstitial fluid. J Parenter Sci Technol 45 (1991) 156-159
21. Warren H.S., and Leclerc C. Adjuvants. In: Delves P.J., and Roitt I.M. (Eds). Encyclopedia of immunology. 2nd ed (1998), Acad Press, San Diego 36-39
22. Hem S.L. Elimination of aluminum adjuvants. Vaccine 20 Suppl. 3 (2002) S40-S43
23. Guis S., Pellissier J.F., Nicoli F., et al. HLA-DRB1*01 and macrophagic myofasciitis. Arthritis Rheum 46 (2002) 2535-2537
24. Ginaldi L., De Martinis M., D'Ostilio A., Marini L., Loreto M.F., and Quaglino D. The immune system in the elderly: III. Innate immunity. Immunol Res 20 (1999) 117-126
25. Brewer J.M., Conacher M., Hunter C.A., Mohrs M., Brombacher F., and Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediating signalling. J Immunol 163 (1999) 6448-6454
26. Skowera A., Cleare A., Blair D., Bevis L., Wessely S.C., and Peakman M. High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. Clin Exp Immunol 135 (2004) 294-302
27. Authier F.J., Sauvat S., Champey J., Drogou I., Coquet M., and Gherardi R.K. Chronic fatigue syndrome in patients with macrophagic myofasciitis. Arthritis Rheum 48 (2003) 569-570
28. Etude épidémiologique exploratoire de la myofasciite à macrophages. Analyse des données disponibles sur le lien éventuel entre le VHB et les autres pathologies. Rapport d'étude; October 2003. http://afssaps.sante.fr/htm/10/myofasci/etude.pdf.
29. Landay A., Jessop C., Lenette E., and Levy J. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 338 (1991) 707-712
30. Rook G.A.W., and Zumla A. Gulf war syndrome: is it due to a systemic shift in cytokine balance towards a Th2 profile?. Lancet 349 (1997) 1831-1833
31. Itoh Y., Igarashi T., Tatsuma N., et al. Immunogenetic background of patients with autoimmune fatigue syndrome. Autoimmunity 32 (2000) 193-197
32. Patarca R. Cytokines and chronic fatigue syndrome. Ann NY Acad Sci 933 (2001) 185-200
33. Gherardi R.K., Plonquet A., André Ch., et al. Macrophagic myofasciitis: evidence for chronic local and systemic immune activation associated with persistence of aluminum hydroxide-loaded macrophages in muscle. Neurology 56 Suppl. 3 (2001) A62 [Abstract]